Jessica J Lin
Massachusetts General Hospital · NRG Oncology
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jessica J Lin as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:05 UTC. Open this list on ClinicalTrials.gov
- N/ANCT04881916 · Immune and Genomic Markers in ALK+ NSCLCMassachusetts General Hospital · active not recruiting · Anaplastic Lymphoma Kinase Gene Translocation, Non-Small Cell Lung Cancer · principal investigator
- Ph2NCT03737994 · Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung CancerNational Cancer Institute (NCI) · terminated · Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8 · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:05 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 29 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Overcoming Resistance Mechanisms to Anaplastic Lymphoma Kinase InhibitorsR01CA164273 · NCI · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2019 to 2026 · $416,103 awarded in 2026Same name and institution; not confirmed by an ID
- TMS in preclinical and prodromal AD: Modulation of brain networks and memoryK01AG059894 · NIA · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2019 to 2020 · $130,950 awarded in 2020Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- NRG Oncology Network Group Operations CenterU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Quynh-Thu Xuan Le, ROBERT S. MANNEL, NORMAN WOLMARK · fiscal years 2014 to 2026Named on NCT03737994
Most cited trial papers
Clinical-trial papers with this author name in non-small cell lung cancer, ranked by citations from NIH iCite, fetched 2026-11-12 10:05 UTC. The ranking covers the 200 most relevant of 13 PubMed records, and a shared surname and initials can bring in a namesake. All 13 on PubMed
- 630 citationsRCR 22.9
- Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.N Engl J Med · 2024227 citationsRCR 25.8
- 170 citationsRCR 10.9
- A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor.J Thorac Oncol · 202158 citationsRCR 2.8
- NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations.Cancer Discov · 202453 citationsRCR 5.1
- Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase-Positive Lung Cancer and CNS-Specific Relapse.JCO Precis Oncol · 202237 citationsRCR 2.5
- Final Overall Survival and Long-Term Safety of Lorlatinib in Patients With ALK-Positive NSCLC From the Pivotal Phase 2 Study: A Brief Report.J Thorac Oncol · 202529 citationsRCR 7.3
- 29 citationsRCR 14.5
- Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II study.ESMO Open · 202225 citationsRCR 1.5
- Phase 2 Trial of Consolidative Stereotactic Body Radiation Therapy in Patients With Metastatic Oncogene-driven Non-small Cell Lung Carcinoma Treated With Tyrosine Kinase Inhibitors.Int J Radiat Oncol Biol Phys · 20255 citationsRCR 0.8